Physician profile
Mykhaylo Babenko
NPI 1275883621
$1,654.02
in general payments reported to CMS, 2019-2025
14 companies · $601 in 2025
The $601 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.47 · 2022: $91.75 · 2023: $450 · 2024: $460 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $347.88 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $243.78 | 2024-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $215.87 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $133.70 | 2023-2025 | Nucala, Shingrix, Rotarix |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Dupixent |
| Janssen Pharmaceuticals, INC | $114.77 | 2023-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $112.91 | 2023 | Quviviq |
| Abbvie INC. | $109.08 | 2025 | |
| Lilly USA, LLC | $103.94 | 2024 | Zepbound |
| Abbott Laboratories | $60.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.57 | 2023-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $21.65 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $19.09 | 2025 | Zoryve |
| Pfizer INC. | $16.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mykhaylo Babenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.